Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma

Dan P. Zandberg; Jacob B. Allred; Ari J. Rosenberg; John M. Kaczmar; Paul Swiecicki; Ricklie Julian; Andrew Poklepovic; Jessica R. Bauman; Minh D. Phan; Nabil F. Saba; Edgardo Rivera; Kendrith M. Rowland; Diwakar Davar; Jill Cordes; Alan L. Ho; Miao Zhang; Stephanie Berg; Pamela N. Münster; Gary K. Schwartz

doi:10.1200/jco-25-00759

Abstract

This is the authors' abstract. We don't add key points for this paper.

Avelumab + cetuximab significantly improved PFS versus avelumab alone in patients with advanced cSCC. Alliance A091802 supports a larger confirmatory study with the combination of cetuximab and PD-1:PD-(L)1 blockade.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zandberg et al. (2025) studied this question.

synapsesocial.com/papers/69d9a7011ad561c673684de7 https://doi.org/10.1200/jco-25-00759

View at Publisher

Ask AI

Bookmark

Share

Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma

Abstract

Ask about this paper

Discussion

Cite This Study

Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading